SPTBN4

Across TCGA pan-cancer cohorts, SPTBN4 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated SPTBN4 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher SPTBN4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPTBN4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, LUAD, and UCEC are the cancer types where SPTBN4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.258	0.600	.003	18	view →
LUAD	OS	Median	II,III,IV	0.111	0.750	<.001	18	view →
UCEC	DFS	Median	II,III,IV	0.895	0.428	.010	14	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
PRAD	DFS	Median	All	0.451	0.888	<.001	6	view →
ESCA	DFS	Median	All	0.261	0.539	.027	6	view →
KIRP	DFS	Median	All	0.519	0.920	.003	3	view →
LIHC	OS	Median	All	0.169	0.669	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

SPTBN4–SCLC (OS)

Open the SCLC breakdown →